Medicinal mushroom *Taiwanofungus camphoratus*: A potential cure for cancer

I-Shu Lee¹³, Roland Kirschner², Shui-Tein Chen¹³

¹Antrodia cinnamomea Association of Taiwan Treasure, Taipei city, 106, Taiwan; ²Department of Biomedical Sciences and Engineering, National Central University, Taiwan; ³Institute of Biological Chemistry, Academia Sinica, Taiwan

Corresponding author: I-Shu Lee, Institute of Biological Chemistry, Academia Sinica, 128, Academia Road Sec. 2, Nankang, Taipei 115, Taiwan


Citation: Lee I., Kirschner R., Chen S. Medicinal Mushroom *Taiwanofungus camphoratus*: A potential cure for cancer. *Functional Foods in Health and Disease* 2019; 9(8): 508-520. DOI: https://doi.org/10.31989/ffhd.v9i8.576

ABSTRACT

Based on traditional and folk medicine, mushrooms have been developed into anti-cancer therapeutics. In this article, a brief overview is given of the most important medical mushroom species and their specific anti-cancer functions and mechanisms. *Taiwanofungus camphoratus* (*Antrodia cinnamomea*), is a medical fungus chosen to examine the process from ethnomedicine to developing new products for the market based on scientific, analytic, and experimental evidence. The bioactive compounds have indirect effects in cancer treatment by benefiting the immune system as well as having direct cytotoxic effects on cancer cells.

*Taiwanofungus camphoratus* is a fungus endemic to Taiwan and one of the most popular known alternative remedies for liver cancer in Taiwan. To date, more than 150 liver cancer patients have survived using *T. camphoratus*. The treatment has caused tumor shrinking, as well as the disappearance of a tumor altogether in some cases. The ratio between male and female patients has been nearly equal, with ages ranging between 20-79 years. The most effective candidates are those between the ages of 40-60 years.
The complex mixture of bioactive compounds in natural fruit bodies is a challenge for artificial production in vitro. Particular problems in developing *T. camphoratus* into therapeutics for the global market are its rarity in nature and its close dependence on an endemic tree in Taiwan. These challenges can help promote new solutions which could be utilized in the future with other medical fungi.

**Keywords:** Medicinal mushrooms, anti-cancer therapeutics, *Taiwanofungus camphoratus*, liver cancer.

**INTRODUCTION**

The use of mushrooms as therapeutics dates back to over 2000 years ago, including the use of *Laricifomes officinalis* in Europe and *Ganoderma lingzhi* in China. Fruitbodies of *Piptoporus betulinus* (Figure 1G) found among the items of "Ötzi the Iceman", a 5000-year-old European mummy, were presumably used as a remedy against parasitic worms [1]. The traditional usage of mushrooms in European folk medicine, e.g. of “Judas’ Ear”, *Auricularia auricula-judae* (Figure 1B) gradually disappeared in the 18th and 19th centuries [2]. *Trametes versicolor* (Figure 1I). In the West, mushrooms were used only for ornamental purposes, as opposed to the East where they were used as medicine. However, in comparison to the uninterrupted development and cultivation in East Asia for many centuries, the medical research and usage of mushrooms has experienced a relatively recent revival and development in Western countries. In traditional Chinese medicine and folk medicines, mushrooms have not been used specifically to treat cancer, but have been used for general disease prevention or to treat other diseases. For example, one of the most commonly used medical fungi in Chinese medicine is *Wolfiporia cocos* (“fu ling”). The antitumor properties of medical fungi were discovered mostly through screening them with modern scientific methods. In contrast to other diseases traditionally treated with medical mushrooms, there is little data for mushrooms and the treatment of cancer. Consequently, this may explain why few mushroom-based anticancer therapeutics are available.

Nonetheless, scientific research devoted to anticancer properties of mushrooms started worldwide in the 1960s [2]. In this review, the recent development of a mushroom from Taiwan was examined to illustrate the process from ethnomedicine to new, science-based anticancer therapeutics.
HISTORY AND TRADITIONAL APPLICATION

Taiwanofungus camphoratus is the most studied species of all the fungi with anti-cancer potential activity. Over 900 related scientific research reports have been published in international journals on the anti-cancer potential of T. camphoratus. The following text analyzes T. camphoratus as an example of a medical fungus to illustrate the general process from ethnomedicine to developing new products for the market based on scientific, analytical and experimental evidence.

Antrodia cinnamomea, also known as Antrodia camphorata or Taiwanofungus camphoratus, is a precious and unique edible fungus that grows naturally only on the aromatic tree Cinnamomum kanehirae (Lauraceae; Figure 2), which is native to Taiwan [3, 4]. Wild T. camphoratus grows between June and October at altitudes between 600 and 1800 m. The mushroom prefers to grow on the inner wall inside cavities of old tree trunks. Some fruit bodies grow on moist surfaces of dead trees or on the stumps of cut trees. The growth rate of wild T. camphoratus mushroom is extremely slow. A ten year old fruit body has a dimension of only 25x15x12 mm. The scarcity of the natural host and slow growth rate of the mushroom rendered this treasured mushroom as “ruby in Taiwanese forests”.

T. camphoratus has been used medically by aboriginal tribes for centuries to treat diseases like food and drug intoxication, diarrhea, abdominal pain, hypertension, skin itching, and cancer [5]. The earliest record of a medical recipe against intoxication using T. camphoratus was given by the traditional Chinese medicine doctor Tsai in 1983 with the formula of the recipe reported in 1987 [6]. Scientific study of T. camphoratus started in 1990 and the first reports of its biological functions have been documented in National Digital Library of Theses and Dissertations in Taiwan [7]. Over the past decade, more than 300 papers and 150 Taiwan patent applications for T. camphoratus have been documented [8, 9]. Numerous studies have been conducted on its physiology, biological, and pharmacological properties. Genomic and transcriptomic analyses of the medicinal fungus T. camphoratus have been reported [10]. A 32.15-Mb genome draft containing 9,254 genes was cloned and genome ontology enrichment and pathway analyses were studied to uncover the sexual development and the biosynthesis of sesquiterpenoids, triterpenoids, ergostanes, antroquinonol, and antrocamphin.

Table 1. List of research about Taiwanofungus camphoratus, including synonyms and commercial names in brackets, classification, experimental anticancer evidence, detailed mechanisms, and references. Class = Classification, B = Basidiomycota, Po = Polyporales.
<table>
<thead>
<tr>
<th>Scientific name (synonyms and commercial names)</th>
<th>Class</th>
<th>Experimental anti-cancer evidence</th>
<th>Anti-cancer mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Taiwanofungus camphoratus</strong> <em>(Antrodia camphorata, Antrodia cinnamomea)</em></td>
<td>Po (B)</td>
<td>Human estrogen-non-responsive breast cancer (MDA-MB-231) cells [11]</td>
<td>Non-cytotoxic concentrations (20–80 µg/mL) of extract can inhibit the invasion/migration of highly metastatic MDA-MB-231 cells through suppression of the MAPK signaling pathway.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pancreatic cancer (PANC-1 and AsPC-1) cells [12]</td>
<td>Antroquinonol can induce G1 arrest of the cell cycle and a following apoptosis in human pancreatic cancers through an inhibitory effect on PI3-kinase/Akt/mTOR pathways that in turn down-regulates cell cycle regulators.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pancreatic cancer (PANC-1 and AsPC-1) cells [12]</td>
<td>Antroquinonol also can induce the connection between apoptosis, autophagic cell death and accelerated senescence in cancer cells.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hepatoma (C3A and PLC/PRF/5) cells and xenografted cells in tumor-implanted nude mice</td>
<td>Intervention of MDR gene expressions and COX-2-dependent inhibition of p-AKT.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Transitional cell carcinomas cell lines, superficial cancer cell line RT4, and metastatic cell lines TSGH-8301 and T24</td>
<td>On treatment with the extract at 100 lg/mL, the p53-independent overexpression of p21 with simultaneous down alteration of pRb was observed in RT4. The treatment with the extract at 50 lg/mL also causes simultaneous downregulations of Cdc2 and Cyclin B1, with suppression of the migrating capability of the two cell lines TSGH-8301 and T24, and finally cell death.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A549 cell</td>
<td>The alcohol extract can induce apoptosis in A549 cell by decreasing the expression level of four tumor-related genes, e.g., calpain 1/2 small subunit, galectin-1, Rho GDP inhibitor A. Apoptosis is caused by the mitochondrial pathway and endothelium reticulum stress. The extract also could decrease the production level of eukaryotic translation initiation factor 5A, which is a potential cancer intervention target.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MDA-MB-231 cancer cells</td>
<td>Apoptosis in the MDA-MB-231 cells was followed by release of cytochrome c, activation of caspase-3, -8, and -9, and specific proteolytic cleavage of poly (ADP-ribose) polymerase (PARP). The extract can also inhibit COX-2 protein expression and prostaglandin E2 (PGE2) production in MDA-MB-231 cells,</td>
</tr>
<tr>
<td><strong>Taiwanofungus camphoratus</strong>&lt;br&gt;<em>(Antrodia camphorata, Antrodia cinnamomea)</em></td>
<td><strong>MDA-MB-231 cells</strong> [13]</td>
<td>and induce apoptosis in MDA-MB-231 cells in vitro and in vivo in nude mice.</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Hepatocellular carcinoma cell lines (HepG2, HepG2.2.15, Mahlavu, PLC/PRF/5, SK-Hep1 and Hep3B)</strong> [14]</td>
<td>The cell cycle blockade in extract-treated MDA-MB-231 cells was related to reductions in cyclin D1, cyclin E, CDK4, cyclin A, and proliferating cell nuclear antigen (PCNA), and increased CDK inhibitor p27/KIP and p21.</td>
<td></td>
</tr>
<tr>
<td><strong>Taiwanofungus camphoratus</strong>&lt;br&gt;<em>(Antrodia camphorata, Antrodia cinnamomea)</em></td>
<td><strong>A549 cell</strong> [15]</td>
<td>Antroquinonol can stop the cell-cycle progression and cause following apoptosis. The loss of mitochondrial membrane potential and depletion of mitochondrial content showed the mitochondrial stress caused by antroquinonol, which exhibits anti-cancer activity against the hepatocarcinoma cells through AMPK activation and inhibition of mTOR translational pathway, leading to G1 arrest of the cell-cycle and subsequent cell apoptosis.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Oral cancer (OECM1 and OC-2) cell lines</strong> [16]</td>
<td>Antroquinonol-induced apoptosis related to disrupted mitochondrial membrane potential and activation of caspase 3 and PARP cleavage in A549 cells. Antroquinonol treatment also can down-regulate the expression of apoptosis regulatory proteins Bcl2, which was correlated with the decreased PI3K and mTOR protein levels without altering pro-apoptotic and anti-apoptotic proteins. Antroquinonol changed the expression level of miRNAs in A549 cells.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Liver cancer (PLC/PRF/5) cell line</strong> [17]</td>
<td>The mechanism of growth inhibition was apoptosis induction, resultant of caspase-3 activation and DNA fragmentation.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>The effect was related to a decrease in either the level or activity of VEGF, matrix metalloproteinases (MMP-2, MMP-9 and MT1-MMP), and an increase in the expression of tissue inhibitor of metalloproteinase (TIMP-1 and TIMP-2). The extract can further inhibit activated and inducible NF-kB in both its DNA-binding activity and transcriptional activity, also can inhibit the TNF-a-activated NF-kB dependent reporter gene expression of MMP-9 and VEGF. The extract also exhibited an inhibitory effect on angiogenesis.</td>
<td></td>
</tr>
</tbody>
</table>
MEDICINAL USES OF TAIWANOFUNGUS CAMPHORATUS

The host specificity, scarcity in nature, and slow growth rate makes the large scale production of *T. camphoratus* very difficult. In the last decade, many scientists have tried to identify optimal culture conditions for mass production. Four major culture techniques have developed: submerged liquid fermentation, solid support culture, timber culture, and dish culture. Each culture method has its advantages and disadvantages. For example, the submerged fermentation technique can produce a great amount of *T. camphoratus* mycelia within 2-4 weeks, but the product contains less biologically active compounds. Both the timber and dish cultivations (Figure 2) produce *T. camphoratus* fruiting bodies with most of the biologically active compounds, but the growth of the former takes 0.5-2 years and the latter takes 4-6 months. Since biological activity differs between *T. camphoratus* originating from different cultivation methods and collections in the wild, it is necessary to clearly define the profiles of secondary metabolites and their biological functions to prevent confusion in the of *T. camphoratus* products.

*Figure 2. Processing of Taiwanofungus camphoratus* from nature, liquid culture, solid culture and
cultivation on wood of Cinnamomum kanehirae.

BIOACTIVE COMPOUNDS AND ANTI-CANCER MECHANISM

The most studied biological activities of T. camphoratus are 1) anti-inflammatory activity; 2) cytotoxic activity; 3) hepato-protective activity; 4) antioxidant activity; 5) immune modulatory effect; and 6) miscellaneous activities, such as anti-allergic effect. The anti-cancer activity of T. camphoratus is a combination of its cytotoxic activity and immune modulatory effects.

Recently, in vivo and in vitro studies of the biological functions of T. camphoratus, using extracts or isolated pure compounds, against cancer or tumor cells revealed two mechanisms: the direct cytotoxic activity to inhibit cancerous growths and the stimulation of immune cells to enhance activity of both the innate and adaptive systems to eliminate pathogens or cancerous cells.

In general, the cytotoxic compounds can directly trigger cell apoptosis. The cytotoxic activity of a compound against testing cells is expressed through its half maximum inhibitory concentration (IC$_{50}$), which is the concentration of the compound that inhibits 50% population growth of the tested cells. When the experiment is conducted with both cancer and normal cells, the selectivity index (SI) is used to show the specificity of the drug against cancer cells in comparison to that of the normal cells. The SI was determined by the proportion of the IC$_{50}$ value of cancer cells relative to that of normal cells.

The immune systems can be classified into the innate immune system (i.e. non-specific immune system or in-born immunity system), and adaptive immune system (also known as the acquired immune system or the specific immune system). The innate immune system is made up of cells and mechanisms that defend the host from infection by other organisms. The cells of the innate system recognize and respond to pathogens in a general way. The adaptive immune system is composed of highly specialized cells and processes to eliminate pathogens or prevent their growth. Natural killer (NK) cells hold an important role in immunity and chemo-preventive activity in human beings. They are crucial in innate immunity capturing viruses and killing cancer cells, as well as participating in adaptive immunity.

The innate immune system provides immediate defense against infection by: 1) recruiting immune cells to sites of infection through the production of chemical factors called cytokines; 2) activating the complement cascade to identify bacteria, activate cells, and promote clearance of antibody complexes or dead cells; 3) identifying and removing foreign substances present in organs, tissues, blood and lymph, by specialized white blood cells; 4) activating the adaptive immune system through a process known as antigen presentation; 5) acting as a physical and chemical barrier to infectious agents.
The adaptive immunity creates an immunological memory after an initial response to a specific pathogen, and leads to an enhanced response to subsequent encounters with that pathogen. This process of acquired immunity is the basis of vaccination. Like the innate system, the adaptive system includes both humoral immunity components and cell-mediated immunity components.

Some of these compounds are responsible for the stimulation of the immune system in a way that is shared by many medical mushrooms [18], while other compounds appear to be more specific to *T. camphoratus* and show specific cytotoxic activity against cancer cells. Many biologically active compounds have been isolated from *T. camphoratus* and some of the structures have been determined [19, 20]. The most widely studied components among the numerous isolated compounds of *T. camphoratus* are: 1) antroquinonol and its derivatives; 2) succinic and maleic acid derivatives; 3) triterpenoids; 4) benzenoids; 5) polysaccharides; and 6) volatile essential oils.

Both polysaccharides and volatile essential oils have low cytotoxic activity against normal and cancerous cells. They can activate all the cells of the innate immune system, such as NK cells, and of the adaptive immune system, such as B cells. [21, 22].

**APPLICATION AND GLOBAL MARKETING**

Although the detailed procedure of manufacturing *T. camphoratus* for the market is the secret of companies, some basic information is presented (Figure 7). Fruitbodies collected in hollows of wild old trees of *Cinnamomum kanehirae* are considered the best for accompanying anticancer treatment. However, due to exorbitant prices and concerns of nature conservation the second choice of using fruitbodies from artificial cultivation on wood logs from plantations of *C. kanehirae* is an adequate alternative. Mycelia grown on wood logs or artificial solid substrates are considered the third choice. Mycelia grown in liquid culture are cheaper, particularly when they are not separated from the cultivation medium. Mycelia are less recommended for usage against cancer, but can be utilized in the treatment of less severe diseases and as health food.

Fruitbodies (or mycelia) are frozen or dried and can be extracted with hot water or organic solvents (alcohol) for direct uptake. In order to ensure standardized amounts, dried fruitbodies or mycelia are also powdered to be made into pressed tablets or filled into capsules, or their liquid extract is filled into small vials. Extracts provide the advantage that their compounds can be enriched by concentration and used conveniently as liquid or after spraying the highly concentrated extracts onto globuli also in solid form.

The total number of edible and medicinal fungi is over 2,300 species. Cultivated mushrooms have become popular with over 200 genera of useful macro-fungi in the world. According to the mushroom market reports 2017-trends, analysis, and statistics, the mushroom market will reach
US$50,034.12 million by 2019. Although there are no published figures related to the total world market value of medicinal mushrooms, the market value for *Ganoderma* medicinal mushroom in 1995 was estimated to be about US$1,628.4 million [23]. The market values of the mushroom products were estimated to be US$350 million in China, US$600 million in Korea, US$300 million in Japan, US$215 million in Taiwan, US$91.2 million in Malaysia, US$60 million in Hong Kong, US$2.2 million in Singapore and US$10 million in other countries.

Medicinal mushrooms have emerged as integral ingredients of dietary supplements in the last few decades. It is estimated that between 80 and 85% of all medicinal mushrooms products are derived from the fruiting bodies, which have been either artificially cultured or collected from nature. The total market value of *T. camphoratus* products in Taiwan is estimated to be over US$100 million per year (www.businesstoday.com.tw/article-content-80392-93594).

**SUMMARY**

Medically used macrofungi systematically belong to the orders Agaricales, Auriculariales, Boletales, Hymenochaetales, Polyporales, Russulales, and Tremellales of Agaricomycotina (Basidiomycota) and Hypocreales and Xylariales of Pezizomycotina (Ascomycota). Over 30 species have been identified as having anticancer activity. Research regarding the taxonomy of the species is ongoing and not yet finished. Different strains of the same species and different parts of the same fungus can differ in their biologically active compounds.

Antitumor activity of fungal compounds is exhibited as cancer cell apoptosis, inhibition of cell growth, cell proliferation, and cancer cell metastasis, as well as altered gene or protein expression, indicating a high diversity of anticancer mechanisms.

*Taiwanofungus camphoratus* (synonym *Antrodia cinnamomea*) is an endemic polypore with red fruitbodies that is only formed on a tree of the laurel family also endemic to Taiwan. The fungus has commonly been used in ethnomedicine. Fruitbodies of *T. camphoratus* have the best effect while mycelium from liquid culture has the weakest effect.

Among the main groups of anticancer compounds of *T. camphoratus* γ-dodecalactone (γ-DDL) and polysaccharides are mainly responsible for immunomodulatory effects, whereas cytotoxic effects are exerted by derivatives of antroquinonol as well as succinic and maleic acid, triterpenoids, and benzenoids. The triterpenoids are particularly highly specific for *T. camphoratus* and rich with respect to concentration and structural diversity.

*T. camphoratus* and other medicinal mushrooms play an increasing role in anticancer treatment and in the global market.
ACKNOWLEDGEMENTS

We thank the Herbarium of the National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan, for the permit to photograph specimens of *Ophiocordyceps sinensis* and Mr. Chen-Ching Chen, Taitung, Taiwan, to photograph *Taiwanofungus camphoratus*.

**List of Abbreviations:** 20-deoxy salinomycin, SY-1; a strain of white mouse, BALB/c mice; B-cell lymphoma 2, Bcl-2; Bcl-2-associated X protein, Bax; Cluster of Differentiation 69 (a human protein used as marker of early immune activation), CD69; cytotoxic concentration of a substance causing death to 50% of viable cells, CC50; deoxyribonucleic acid, DNA; fluorescein isothiocyanate/ propidium iodide, FITC/PI; γ-dodecalactone, γ-DDL; gas chromatography–mass spectrometry, GC-MS; half maximum inhibitory concentration, IC50; human breast cancer cell lines, MDA-MB-231 and MCF7; human colon cancer cell line, COLO 205; human glioblastoma cell lines, U87MG and GBM8401; human leukemia cancer cell line, HL-60; human liver carcinoma cell lines, Hep3B, HepG2 and Huh7; human liver cancer cell line marked with Enhanced Green Fluorescent Protein, HepG2-EGFP; human lung cancer cell line, A549; human oral squamous cell carcinoma cell lines, OC-2 and OEC-M; human prostate carcinoma cell lines, DU-145 and LNCaP; interphase arrested at fully grown cell stage, G0/G1 arrest; interphase and mitosis, G2/M phase; interphase (prior to DNA duplication) characterized by DNA fragmentation, sub-G1; messenger ribonucleic acid, mRNA; Michigan Cancer Foundation-7, MCF-7; micro ribonucleic acids, microRNAs; natural killer cells, NK cells; natural killer cells isolated from human peripheral-blood mononuclear cells, hPB-NK; neural cell adhesion molecule, CD56+; Poly(ADP-ribose) polymerase, PARP; selectivity index (proportion of the IC50 value of cancer cells relative to that of normal cells), SI; tricarboxylic acid cycle, TCA; terminal deoxynucleotidyl transferase dUTP nick end labeling, TUNEL.

**Competing Interests:** The authors declare no conflict of interest.

**Authors’ Contributions:** All authors contributed to this review.

**REFERENCES**


